Skip to main content

Table 1 The baseline characteristics of ICC patients in training and validation sets

From: The preoperative prognostic value of the radiomics nomogram based on CT combined with machine learning in patients with intrahepatic cholangiocarcinoma

Variable Whole set (n = 101) Training set (n = 77) Validation set (n = 24) p
Sex, male, n (%) 55 (54.5) 40 (51.9) 15 (62.5) 0.365
Age, mean ± SD, years 58.2 ± 10.8 58.5 ± 10.9 56.9 ± 10.7 0.458
Hypertension, n (%)     0.995
 Yes 21 (20.8) 16 (20.8) 5 (20.8)  
 No 80 (79.2) 61 (79.2) 19 (79.2)  
Diabetes, n (%)     0.932
 Yes 8 (7.9) 6 (7.8) 2 (8.3)  
 No 93 (92.1) 71 (92.2) 22 (91.7)  
Hepatitis B, n (%) 27 (26.7) 21 (27.3) 6 (25.0) 0.826
Liver cirrhosis, n (%)     0.074
 Present 13 (12.9) 7 (9.1) 6 (25.0)  
 Absent 88 (87.1) 70 (90.9) 18 (75.0)  
Hypersplenism, n (%)     0.421
 Yes 2 (2.0) 1 (1.3) 1 (4.2)  
 No 99 (98.0) 76 (98.7) 23 (95.8)  
ALT, mean ± SD, IU/L 36.0 ± 38.6 33.8 ± 37.3 43.3 ± 42.4 0.131
AST, mean ± SD, IU/L 38.7 ± 34.9 35.8 ± 34.4 48.6 ± 35.7 0.024
ALB, mean ± SD, g/L 41.6 ± 4.1 41.8 ± 3.7 41.2 ± 5.1 0.941
TBIL, mean ± SD, μmol/L 15.2 ± 16.5 13.6 ± 8.2 20.6 ± 30.7 0.095
PT, mean ± SD, s 11.7 ± 1.6 11.5 ± 1.0 12.3 ± 2.8 0.357
INR, mean ± SD 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.2 0.362
AFP, mean ± SD, ng/mL 40.0 ± 189.7 29.1 ± 150.4 74.6 ± 283.6 0.624
CA 125, mean ± SD, U/mL 50.0 ± 82.8 47.3 ± 67.5 58.0 ± 120.9 0.106
CA 19-9, mean ± SD, U/mL 322.6 ± 393.5 321.2 ± 404.3 327.5 ± 365.4 0.515
CEA, mean ± SD, ng/mL 18.2 ± 71.1 13.0 ± 36.1 36.9 ± 137.6 0.333
Tumor size, n (%)     0.455
 ≤ 5 cm 27 (26.7) 22 (28.6) 5 (20.8)  
 > 5 cm 74 (73.3) 55 (71.4) 19 (79.2)  
Differentiation     0.084
 Well 1 (1.0) 0 1 (4.2)  
 Moderate 36 (35.6) 31 (40.3) 5 (20.8)  
 Poor 57 (56.4) 40 (51.9) 17 (70.8)  
 Unclear 7 (6.9) 6 (7.8) 1 (4.2)  
OS, mean ± SD, m 19.9 ± 17.6 21.3 ± 18.6 15.6 ± 13.3 0.300
  1. Abbreviations: ICC Intrahepatic cholangiocarcinoma, SD Standard deviation, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALB Albumin, TBIL Total bilirubin, PT Prothrombin time, INR International normalized ratio, AFP Alpha fetoprotein, CA Carbohydrate antigen, CEA Carcinoembryonic antigen, OS Overall survival